(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Devastating funding cuts from international donors are hitting countries hardest affected by HIV — but many are showing ...

Global Fund notes that the US has contributed more than $26.31 billion to date and pledged up to $6 billion for the Seventh ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

The Senate will be voting on a Trump-proposed rescissions package July 18. The package aims to cut funding for foreign aid already appropriated for years by a bipartisan Congress. Included is The ...